1. SF3B1 and BAP1 mutations in blue nevus-like melanoma
- Author
-
Uwe Hillen, Tobias Schimming, Michael Emberger, Heinz Kutzner, Richard A. Scolyer, Antje Sucker, Hansgeorg Müller, Thomas Mentzel, Ioana Cosgarea, Johannes van de Nes, Bastian Schilling, Thomas Wiesner, Annette Paschen, Henning Reis, Elisabeth Livingstone, Arno Rütten, Louise Jackett, Simone L. Scholz, Klaus G. Griewank, Dirk Schadendorf, Rajmohan Murali, Lisa Zimmer, and Inga Möller
- Subjects
Adult ,Pathology ,medicine.medical_specialty ,Skin Neoplasms ,Adolescent ,EIF1AX ,Medizin ,Biology ,Gene mutation ,medicine.disease_cause ,Article ,Pathology and Forensic Medicine ,Diagnosis, Differential ,Young Adult ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Nevus, Blue ,medicine ,Humans ,Nevus ,Child ,skin and connective tissue diseases ,Melanoma ,neoplasms ,Aged ,Aged, 80 and over ,BAP1 ,Mutation ,GNA11 ,Tumor Suppressor Proteins ,Middle Aged ,Phosphoproteins ,medicine.disease ,GTP-Binding Protein alpha Subunits ,Child, Preschool ,030220 oncology & carcinogenesis ,GTP-Binding Protein alpha Subunits, Gq-G11 ,RNA Splicing Factors ,Ubiquitin Thiolesterase ,GNAQ - Abstract
Blue nevi are melanocytic tumors originating in the cutaneous dermis. Malignant tumors may arise in association with or resembling blue nevi, so called ‘blue nevus-like melanoma’, which can metastasize and result in patient death. Identifying which tumors will behave in a clinically aggressive manner can be challenging. Identifying genetic alterations in such tumors may assist in their diagnosis and prognostication. Blue nevi are known to be genetically related to uveal melanomas (eg, both harboring GNAQ and GNA11 mutations). In this study, we analyzed a large cohort (n=301) of various morphologic variants of blue nevi and related tumors including tumors diagnosed as atypical blue nevi (n=21), and blue nevus-like melanoma (n=12), screening for all gene mutations known to occur in uveal melanoma. Similar to published reports, we found the majority of blue nevi harbored activating mutations in GNAQ (53%) or GNA11 (15%). In addition, rare CYSLTR2 (1%) and PLCB4 (1%) mutations were identified. EIF1AX, SF3B1, and BAP1 mutations were also detected, with BAP1 and SF3B1 R625 mutations being present only in clearly malignant tumors (17% (n=2) and 25% (n =3) of blue nevus-like melanoma, respectively). In sequencing data from a larger cohort of cutaneous melanomas, this genetic profile was also identified in tumors not originally diagnosed as blue nevus-like melanoma. Our findings suggest that the genetic profile of coexistent GNAQ or GNA11 mutations with BAP1 or SF3B1 mutations can aid the histopathological diagnosis of blue nevus-like melanoma and distinguish blue nevus-like melanoma from conventional epidermal-derived melanomas. Future studies will need to further elucidate the prognostic implications and appropriate clinical management for patients with tumors harboring these mutation profiles.
- Published
- 2017
- Full Text
- View/download PDF